ArticleNeurogastroenterology and motility2025
Predicting Symptomatic Response to Prokinetic Treatment Using Gastric Alimetry.
Article in Neurogastroenterology and motility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Body Surface Gastric Mapping Improves Diagnosis of Gastric Motility Disorders.Current gastroenterology reports · 2026Review
- Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: 'Auckland Classification' v1.0.Neurogastroenterology and motility · 2026Article
- Body Surface Gastric Mapping (BSGM): Is This the Future Standard of Care Noninvasive Test for Gastric Symptoms in Pediatrics?Neurogastroenterology and motility · 2026Article
- Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.Journal of neurogastroenterology and motility · 2026Article
- Adolescent Normative Intervals for Body Surface Gastric Mapping: Spectral Analysis.Neurogastroenterology and motility · 2026Article
- Patient-centered gastrointestinal function assessment technologies: a paradigm shift from traditional approaches to non-invasive innovations.Frontiers in physiology · 2026Review
- Distinct Subgroups in Gastroparesis Defined by Simultaneous Body Surface Gastric Mapping and Gastric Emptying Breath Testing.Neurogastroenterology and motility · 2025Article
- Body surface gastric mapping facilitates the management of pediatric disorders of gut-brain interaction.Therapeutic advances in gastroenterology · 2025Review
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
backgroundChronic neurogastroduodenal disorders are challenging to manage, with therapy often initiated on a trial and error basis. Prokinetics play a significant role in management, but responses are variable and have been associated with adverse events, impacting widespread use. We investigated whether body surface gastric mapping (BSGM) biomarkers (using Gastric Alimetry) could inform patient selection for prokinetic therapy.
methodsPatients with chronic gastroduodenal symptoms taking oral prokinetic agents, regardless of gastric emptying status, were prospectively recruited and underwent BSGM (30 m baseline, 482 kcal standardized meal, 4 h postprandial recording) while off-prokinetic agents. Patients were followed up with daily symptom diaries. A subset was compared to matched patients not taking prokinetic agents. Prokinetic responders were defined based on symptom improvement greater than a minimum clinically important difference methodology. KEY
resultsForty-two patients (88% female; median age 36; median BMI 26) taking prokinetics were analyzed. Prokinetic prescribing, compared to matched patients, was independent of BSGM metrics (p > 0.15). In patients on existing prokinetics (withheld for BSGM), lower amplitudes predicted reduced symptom burden, whereas low rhythm stability predicted a worse symptom burden (p < 0.05). In prokinetic-naive patients (i.e., started on a prokinetic during the study), a lower postprandial amplitude predicted responders (mean 37.5 ± 10.6 uV in responders [n = 5] vs. mean 54.8 ± 6.6 uV among nonresponders [n = 3], p = 0.047).
conclusionsGastric Alimetry biomarkers may help in the prediction of prokinetic response in patients with chronic gastroduodenal symptoms. Lower postprandial amplitudes, indicating a reduced meal response, appear to predict benefit, while impaired rhythm stability predicted poorer therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.